1. **ISAM Standing Towards the Tobacco Industry**

The mission of the Society is to promote and advance aerosol science internationally, focused on health effects of inhaled aerosols including inhaled drug delivery for prevention and treatment of human disease. As such, ISAM is committed to the prevention and treatment of diseases caused by the use of tobacco and other inhalants. Therefore, the ISAM and its members, staff and activities will not support activities of the tobacco industry that promote the public’s exposure to tobacco products, because the inhalation and oral use of tobacco products and byproducts has been proven to cause and/or aggravate a wide spectrum of diseases and conditions.

The ISAM follows the same tobacco involvement policy as that adopted by the American Thoracic Society (www.thoracic.org). Highlights of these policies include that the ISAM

a. Does not accept for its conferences any research that has been funded by tobacco entities;

b. Does not accept anyone who has a current relationship with a tobacco entity, or has had one within the preceding 12 months

   a. as a planner or oral presenter for its conferences, or as a Society leader; anyone who has a current relationship with a tobacco entity, or has had one within the preceding 12 months;

   b. as Chair, Co-Chair, or other panelist for an official ISAM document such as a guideline or statement;

   c. to be a recipient of ISAM awards

The ISAM’s knowledge and management of an individual’s conflict of interest due to a relationship with the tobacco industry relies on the self-disclosure of ISAM members and other participants in ISAM activities. This disclosure is achieved through ISAM procedures for disclosure of conflict of interest and the efforts of the Society’s Officers; Board members; Editors; Chairs of ISAM networking groups, committees, task forces, and scientific and educational programs; and ISAM office staff to carry out this policy according to established ISAM procedures.
The ISAM supports the tobacco involvement policy of its official journal, the *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, regarding research funded by tobacco entities, i.e. that the journal will not publish any research that has been funded by tobacco entities or submitted by an author or co-author that has or had within the 12 months prior to submission a relationship with a tobacco entity.

2. **Other Nicotine Delivery Systems**

Disclosure of professional or other financial relationships with manufacturers and marketers of non-tobacco nicotine delivery systems such as e-cigarettes, personal vaporizers, vape pens, e-cigs, e-hookah, or vaping devices (products that produce an aerosolized mixture containing flavored liquids and nicotine that is inhaled by the user), is also required.

Involvement with commercial entities that manufacture or market non-tobacco nicotine delivery systems and are unrelated to tobacco companies is not prohibited and does not cause the automatic limitations on an individual’s participation in ISAM activities specified in this policy. It may, however, be judged as likely to compromise a specific activity or the individual’s effectiveness in it, and therefore disqualify the individual for a specific activity, or require recusal from specific aspects of an activity.

Last modified August 26, 2019.